• Email Us: [email protected]
  • Contact Us: +1 718 874 1545
  • Skip to main content
  • Skip to primary sidebar

Medical Market Report

  • Home
  • All Reports
  • About Us
  • Contact Us

Supply fears lead EU vaccine industry to seek home comforts

September 17, 2021 by David Barret Leave a Comment

September 17, 2021

By Ludwig Burger and Patricia Weiss

FRANKFURT (Reuters) – European companies playing key supporting roles in COVID-19 vaccine manufacturing are working to move production and supply chains closer to their customers to guard against trade restrictions that have interrupted supplies during the pandemic.

Germany’s Merck KGaA, whose Life Science unit is one of the world’s largest makers of bioreactor gear and supplies, told Reuters it is pushing to spread its production network geographically so that fewer shipments have to cross customs borders.

U.S. regulations in particular, which give priority to companies fulfilling U.S. government contracts, have posed a challenge for Merck as its seeks to meet soaring demand for supplies such as sterile fermentation bags and filters.

But the United States is not the only country engaging in what some call vaccine nationalism. India barred vaccine exports in mid-April to focus on its domestic immunisation drive as infections exploded across the country, upsetting the inoculation plans of many African and South Asian countries.

In the wake of production shortfalls at AstraZeneca earlier this year, the European Union imposed an export-monitoring scheme and accused Britain of withholding COVID-19 vaccine volumes that it said should be shared with the EU.

“Every forward-looking decision we have made integrated the geographical dimension into it,” Chief Executive Belen Garijo told Reuters. “In the context of the trade constraints that we have seen, we have enhanced our global diversification any time we had the chance,” she added.

At Rentschler Biopharma SE, a German contract manufacturer for major pharma companies that is helping to produce CureVac’s COVID-19 vaccine candidate, the pandemic triggered a review of its procurement routes.

“The coronavirus crisis gave us an important push to bring our supply chains closer to home. We decided to source most of our equipment in Europe so that we are no longer as dependent on the United States,” said Chief Executive Frank Mathias, naming sterile bags for bioreactors as an example. He would not name suppliers.

Mathias said supply chains collapsed earlier this year when the United States commandeered certain volumes for domestic vaccine producers.

The U.S. Defense Production Act with its system of rated orders that prioritise U.S. crisis response, also hobbled Merck’s ability to serve vaccine makers elsewhere in the world.

In response, Merck in March laid out plans to invest 25 million euros in France to make disposable plastic materials for bioreactors, an essential input for COVID-19 vaccine manufacturing.

The new site, Merck’s first such facility in Europe, will likely come on stream at the end of 2021, adding to similar production lines in runs in the U.S. and China.

That followed it investing $47 million in its U.S. facilities in Massachusetts and New Hampshire in December, at the time touted as strengthening its global output to meet unprecedented demand.

“The pandemic has been a wakeup call,” said Merck’s Garijo. “You want to have a global footprint in order to be able to deal with potential trade constraints.”

Family-controlled Merck also makes prescription drugs and chemicals for semiconductor production, but its Life Science unit, mostly made up of businesses formerly known as Millipore and Sigma Aldrich, has become its main earnings driver.

Its competitors include Thermo Fisher, Danaher and Sartorius.

In another move to avoid long transport routes and any fallout from international wrangling, German family-owned vaccine maker IDT Biologika earlier this year laid out plans to invest more than 100 million euros to produce AstraZeneca’s COVID-19 vaccine in collaboration with the Anglo-Swedish drugmaker.

The production line, currently set to come on stream in 2023, would be designed to churn out Astra’s shots or other vaccines of the same viral vector class, to the tune of at least 360 million doses a year.

IDT would make the active ingredient and mix, bottle and pack the final product, combining in one place a suite of production steps that are currently widely scattered.

IDT said the project was on track but declined to comment further. The company has said Germany’s federal health ministry had assisted in the project but the investment was not subsidized.

Retooling production networks in a pharma sector that has for decades relied on cross-border exchange and international division of labour can only be done in incremental steps, cautioned Merck CEO Garijo.

“You cannot move a factory from one day to the other, this takes time,” she said.

(Reporting by Ludwig Burger and Patricia Weiss; Editing by Hugh Lawson)

Source Link Supply fears lead EU vaccine industry to seek home comforts

David Barret
David Barret

Related posts:

  1. U.S. Ex-Presidents Bush, Clinton, Obama band together to aid Afghan refugees
  2. Twitter re-opens its account verification process after another pause
  3. Apple’s new MagSafe wallet can be located with the ‘Find My’ app if it goes missing
  4. Report: NBA won’t mandate vaccine for players

Filed Under: News

Reader Interactions

Leave a Reply Cancel reply

Your email address will not be published. Required fields are marked *

Primary Sidebar

  • The Universe May End With A Big Crunch – And There’s Just 20 Billion Years To Go
  • Interstellar Comet 3I/ATLAS Found To Have “Extreme Abundance Ratio” Of Iron And Nickel
  • The Fundamental Forces Of The Universe Are Getting Weaker, New Paper Suggests
  • At Least 541 Million Years Old, These Might Be The First Animals To Evolve On Planet Earth
  • We May Finally Know Why Women Live Longer Than Men
  • Jane Goodall, Pioneering Scientist Who First Discovered Tool-Use In Chimps, Dies At 91
  • Trump Orders Release Of Classified Files On The Mysterious Disappearance Of Amelia Earhart
  • Proof Of Complex Organic Molecules In Enceladus’s Ocean: “You Have Everything You Need To Form Life”
  • Long COVID Risk In Kids Found To Double After Their Second COVID-19 Infection
  • “One Of The Most Extreme Environmental Events On Earth” Unfolded 6.2 Million Years Ago
  • GW190521 May Be Evidence Of Another Universe “Connected To Our Universe Through A Throat”, Scientists Claim
  • Physicists Find A Way Around Heisenberg’s Uncertainty Principle, One Of The Most Frustrating Concepts In Physics
  • AI-Generated Genomes Used To Produce Functional, Bacteria-Killing Viruses In World First
  • Meet The Pocket Sharks: They’re Rare, They’re Tiny, And They’re Something Of A Mystery
  • The Great Comet Of 1997 Was Visible To The Naked Eye For A Record 569 Days
  • In The Soil Of Easter Island, Scientists Found An Anti-Aging Drug That Changed Medicine Forever
  • Interstellar Comet 3I/ATLAS Shows “Extreme Negative Polarization”. What Does That Mean?
  • “Agreeable To The Taste” Like A Sirloin Steak: The People Who Ate Mammoth Meat In The 20th Century
  • Too Much Alcohol For Too Long Can Stop Liver Healing, Even After Quitting – Now We Know Why
  • Meet The Only Mouse Known To Howl At The Moon
  • Business
  • Health
  • News
  • Science
  • Technology
  • +1 718 874 1545
  • +91 78878 22626
  • [email protected]
Office Address
Prudour Pvt. Ltd. 420 Lexington Avenue Suite 300 New York City, NY 10170.

Powered by Prudour Network

Copyrights © 2025 · Medical Market Report. All Rights Reserved.

Go to mobile version